Skip to Content

TAK-875 Enters into Phase III Clinical Trials for the Treatment of Type 2 Diabetes in Japan

Osaka, Japan, September 12, 2011? Takeda Pharmaceutical Company Limited (“Takeda”) announced that TAK-875 has entered into phase III clinical trials for the treatment of type 2 diabetes in Japan.

TAK-875 is an agonist of GPR40, one of the G-protein-coupled receptors(GPCR)* expressed in pancreatic islet cells, which has a novel mechanism of action for type 2 diabetes, discovered by Takeda based on its GPCR research. It works by increasing insulin secretion in a glucose-dependent manner, which is different from the mechanisms of sulfonylurea. TAK-875 is expected to allow patients with type 2 diabetes to have improved glycemic effects with low risk of inducing hypoglycemia.

Takeda has initiated 3 phase III clinical trials, including a multi-center, double-blind controlled trial which will evaluate the efficacy and safety of TAK-875, orally administered, compared to placebo. The study will be conducted in patients with type 2 diabetes who are not achieving adequate glycemic control through diet and exercise therapies alone.

“TAK-875 is the first GPR-40 agonist to reach clinical development and expected to be a novel treatment option,” said Nancy Joseph-Ridge, M.D., Corporate Officer and General Manager, Pharmaceutical Development Division of Takeda. “We are developing TAK-875 globally, with Japan being the first region to begin phase III trials. By doing so, this will provide a new diabetes treatment option for patients and healthcare professionals as efficiently as possible.”

*GPCRs are cell surface receptors involved in a variety of important physiological activity in the cells, like controlling of blood pressure, blood glucose and so on.


Posted: September 2011